Novartis

Digital

Rare disease, repurposing and the role of AI

Novartis launches digital health hub in Canada

Novartis is opening a new digital health innovation hub in Canada to help develop “scalable, digital solutions” for patients and healthcare providers.

News

Novartis’ big bet on inclisiran nears fruition, as CHMP back...

Novartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering drug inclisiran – and the Swiss pharma is now a step closer to

News

NICE changes its mind on Novartis’ progressive MS drug Mayze...

UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance.

News

Novartis' bid to expand use of SMA gene therapy delayed afte...

Analysts have said the FDA’s request for a new trial will delay Novartis’ intrathecal formulation of its spinal muscular atrophy (SMA) gene therapy in older patients until 2023, potentially

White Papers

Preparing for a decade of radical change in pharma

Transformational value - preparing for a decade of radical c...

The pharmaceutical industry is at an inflection point, where ground-breaking innovation must be translated into transformational value for patients, healthcare professionals and society.

News